(S)-2-(2-((S)-2-((S)-1-((6S,9S,12S,15S,18S)-15-((1H-imidazol-4-yl)methyl)-1-amino-18-(4-aminobutyl)-6-((S)-1-((S)-5-guanidino-2-((S)-5-oxopyrrolidine-2-carboxamido)pentanoyl)pyrrolidine-2-carboxamido)-12-(hydroxymethyl)-1-imino-9-isobutyl-7,10,13,16,19-pentaoxo-2,8,11,14,17,20-hexaazadocosane)pyrrolidine-2-carboxamido)hexanamido)-2-methylpropanamido)-3-(4-bromophenyl)propanoic acid

ID: ALA4077505

Chembl Id: CHEMBL4077505

PubChem CID: 137649554

Max Phase: Preclinical

Molecular Formula: C69H109BrN22O16

Molecular Weight: 1582.67

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCC(=O)N1)C(=O)NC(C)(C)C(=O)N[C@@H](Cc1ccc(Br)cc1)C(=O)O

Standard InChI:  InChI=1S/C69H109BrN22O16/c1-6-7-14-44(61(102)90-69(4,5)66(108)89-49(65(106)107)32-39-20-22-40(70)23-21-39)84-62(103)51-18-12-29-91(51)54(95)35-79-55(96)42(15-8-9-26-71)82-59(100)48(33-41-34-76-37-80-41)87-60(101)50(36-93)88-58(99)47(31-38(2)3)86-56(97)43(16-10-27-77-67(72)73)83-63(104)52-19-13-30-92(52)64(105)46(17-11-28-78-68(74)75)85-57(98)45-24-25-53(94)81-45/h20-23,34,37-38,42-52,93H,6-19,24-33,35-36,71H2,1-5H3,(H,76,80)(H,79,96)(H,81,94)(H,82,100)(H,83,104)(H,84,103)(H,85,98)(H,86,97)(H,87,101)(H,88,99)(H,89,108)(H,90,102)(H,106,107)(H4,72,73,77)(H4,74,75,78)/t42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-/m0/s1

Standard InChI Key:  OTIXLTRXSJVNSB-RZGVDQIZSA-N

Alternative Forms

1. Parent:

   

   ALA4077505

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 1582.67

Molecular Weight (Monoisotopic): 1580.7575

AlogP: ┄

#Rotatable Bonds: ┄

Polar Surface Area: ┄

Molecular Species: ┄

HBA: ┄

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): ┄

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: ┄

CX LogP: ┄

CX LogD: ┄

Aromatic Rings: ┄

Heavy Atoms: ┄

QED Weighted: ┄

Np Likeness Score: ┄

References

1. McKinnie SMK, Wang W, Fischer C, McDonald T, Kalin KR, Iturrioz X, Llorens-Cortes C, Oudit GY, Vederas JC..  (2017)  Synthetic Modification within the "RPRL" Region of Apelin Peptides: Impact on Cardiovascular Activity and Stability to Neprilysin and Plasma Degradation.,  60  (14): [PMID:28685579] [10.1021/acs.jmedchem.7b00723]

2. Fernandez KX, Fischer C, Vu J, Gheblawi M, Wang W, Gottschalk S, Iturrioz X, Llorens-Cortés C, Oudit GY, Vederas JC..  (2021)  Metabolically stable apelin-analogues, incorporating cyclohexylalanine and homoarginine, as potent apelin receptor activators.,  12  (8.0): [PMID:34458742] [10.1039/D1MD00120E]

Source

Source(1):

• Scientific Literature